NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets
released its latest key findings for all current investors, traders, and shareholders of BiondVax Pharmaceuticals, Ltd.
(NASDAQ:BVXV), MercadoLibre, Inc. (NASDAQ:MELI), 1-800 FLOWERS.COM, Inc. (NASDAQ:FLWS), Redhill Biopharma, Ltd. (NASDAQ:RDHL),
Mountain Province Diamonds, Inc. (NASDAQ:MPVD), and Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), including updated fundamental
summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
BVXV DOWNLOAD: http://Fundamental-Markets.com/register/?so=BVXV
MELI DOWNLOAD: http://Fundamental-Markets.com/register/?so=MELI
FLWS DOWNLOAD: http://Fundamental-Markets.com/register/?so=FLWS
RDHL DOWNLOAD: http://Fundamental-Markets.com/register/?so=RDHL
MPVD DOWNLOAD: http://Fundamental-Markets.com/register/?so=MPVD
RYTM DOWNLOAD: http://Fundamental-Markets.com/register/?so=RYTM
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine BiondVax
Pharmaceuticals, Ltd. (NASDAQ:BVXV), MercadoLibre, Inc. (NASDAQ:MELI), 1-800 FLOWERS.COM, Inc. (NASDAQ:FLWS), Redhill Biopharma,
Ltd. (NASDAQ:RDHL), Mountain Province Diamonds, Inc. (NASDAQ:MPVD), and Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on a fundamental
level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy,
management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to
today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in this release was accessed June 1st, 2018. Percentage calculations
are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
BIONDVAX PHARMACEUTICALS, LTD. (BVXV) REPORT OVERVIEW
BiondVax Pharmaceuticals' Recent Financial Performance
BiondVax Pharmaceuticals is expected to report earnings on August 30th, 2018. The report will be for the fiscal period ending
June 30th, 2018. The reported EPS for the same quarter last year was -$0.74. The estimated EPS forecast for the next fiscal year is
-$0.04 and is expected to report on April 29th, 2019.
To read the full BiondVax Pharmaceuticals, Ltd. (BVXV) report, download it here: http://Fundamental-Markets.com/register/?so=BVXV
-----------------------------------------
MERCADOLIBRE, INC. (MELI) REPORT OVERVIEW
MercadoLibre's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, MercadoLibre reported revenue of $320.98MM vs $269.68MM (up
19.02%) and basic earnings per share -$0.29 vs $1.10. For the twelve months ended December 31st, 2017 vs December 31st, 2016,
MercadoLibre reported revenue of $1,398.10MM vs $844.40MM (up 65.57%) and basic earnings per share $0.31 vs $3.09 (down 89.97%).
MercadoLibre is expected to report earnings on August 2nd, 2018. The report will be for the fiscal period ending June 30th, 2018.
The reported EPS for the same quarter last year was $0.61. The estimated EPS forecast for the next fiscal year is $2.35 and is
expected to report on February 28th, 2019.
To read the full MercadoLibre, Inc. (MELI) report, download it here: http://Fundamental-Markets.com/register/?so=MELI
-----------------------------------------
1-800 FLOWERS.COM, INC. (FLWS) REPORT OVERVIEW
1-800 FLOWERS.COM's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, 1-800 FLOWERS.COM reported revenue of $238.55MM vs $233.72MM
(up 2.07%) and basic earnings per share -$0.13 vs -$0.17. For the twelve months ended June 30th, 2017 vs June 30th, 2016, 1-800
FLOWERS.COM reported revenue of $1,193.63MM vs $1,173.02MM (up 1.76%) and basic earnings per share $0.68 vs $0.57 (up 19.30%).
1-800 FLOWERS.COM is expected to report earnings on August 23rd, 2018. The report will be for the fiscal period ending June 30th,
2018. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is $0.53 and
is expected to report on August 23rd, 2018.
To read the full 1-800 FLOWERS.COM, Inc. (FLWS) report, download it here: http://Fundamental-Markets.com/register/?so=FLWS
-----------------------------------------
REDHILL BIOPHARMA, LTD. (RDHL) REPORT OVERVIEW
Redhill Biopharma's Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Redhill Biopharma reported revenue of $4.01MM vs $0.10MM
(up 3,867.33%) and basic earnings per share -$2.58 vs -$2.29. Redhill Biopharma is expected to report earnings on July 24th, 2018.
The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.60. The
estimated EPS forecast for the next fiscal year is -$1.30 and is expected to report on February 28th, 2019.
To read the full Redhill Biopharma, Ltd. (RDHL) report, download it here: http://Fundamental-Markets.com/register/?so=RDHL
-----------------------------------------
MOUNTAIN PROVINCE DIAMONDS, INC. (MPVD) REPORT OVERVIEW
Mountain Province Diamonds' Recent Financial Performance
Mountain Province Diamonds is expected to report earnings on August 8th, 2018. The report will be for the fiscal period ending
June 30th, 2018. The reported EPS for the same quarter last year was $0.04.
To read the full Mountain Province Diamonds, Inc. (MPVD) report, download it here: http://Fundamental-Markets.com/register/?so=MPVD
-----------------------------------------
RHYTHM PHARMACEUTICALS, INC. (RYTM) REPORT OVERVIEW
Rhythm Pharmaceuticals' Recent Financial Performance
Rhythm Pharmaceuticals is expected to report earnings on August 13th, 2018. The report will be for the fiscal period ending June
30th, 2018. The estimated EPS forecast for the next fiscal year is -$2.35 and is expected to report on March 11th, 2019.
To read the full Rhythm Pharmaceuticals, Inc. (RYTM) report, download it here: http://Fundamental-Markets.com/register/?so=RYTM
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for
over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide.
Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck®
certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation
holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered
Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA®
charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including
policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release
should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at
compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets,
Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the
opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material
provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication
of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment
adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer,
disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network
manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
